150 related articles for article (PubMed ID: 2145931)
1. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.
Langan-Fahey SM; Tormey DC; Jordan VC
Eur J Cancer; 1990; 26(8):883-8. PubMed ID: 2145931
[TBL] [Abstract][Full Text] [Related]
2. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.
Fabian C; Tilzer L; Sternson L
Biopharm Drug Dispos; 1981; 2(4):381-90. PubMed ID: 7317574
[TBL] [Abstract][Full Text] [Related]
3. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.
Robinson SP; Langan-Fahey SM; Jordan VC
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1769-76. PubMed ID: 2632258
[TBL] [Abstract][Full Text] [Related]
4. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
[TBL] [Abstract][Full Text] [Related]
5. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.
Johnston SR; Haynes BP; Sacks NP; McKinna JA; Griggs LJ; Jarman M; Baum M; Smith IE; Dowsett M
Breast Cancer Res Treat; 1993 Dec; 28(3):241-50. PubMed ID: 8018953
[TBL] [Abstract][Full Text] [Related]
6. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E; Mercier T; Zanolari B; Cruchon S; Guignard N; Buclin T; Leyvraz S; Zaman K; Csajka C; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(32):3402-14. PubMed ID: 21094101
[TBL] [Abstract][Full Text] [Related]
7. Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
Fotoohi AK; Karim H; Lafolie P; Pohanka A; Östervall J; Hatschek T; Vitols S
Ther Drug Monit; 2016 Apr; 38(2):239-45. PubMed ID: 26485084
[TBL] [Abstract][Full Text] [Related]
8. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.
Jordan VC
Breast Cancer Res Treat; 1982; 2(2):123-38. PubMed ID: 6184101
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.
Kisanga ER; Gjerde J; Guerrieri-Gonzaga A; Pigatto F; Pesci-Feltri A; Robertson C; Serrano D; Pelosi G; Decensi A; Lien EA
Clin Cancer Res; 2004 Apr; 10(7):2336-43. PubMed ID: 15073109
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue.
Pujol H; Girault J; Rouanet P; Fournier S; Grenier J; Simony J; Fourtillan JB; Pujol JL
Cancer Chemother Pharmacol; 1995; 36(6):493-8. PubMed ID: 7554041
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer.
Wiebe VJ; Benz CC; Shemano I; Cadman TB; DeGregorio MW
Cancer Chemother Pharmacol; 1990; 25(4):247-51. PubMed ID: 2136809
[TBL] [Abstract][Full Text] [Related]
12. Identification and biological activity of tamoxifen metabolites in human serum.
Kemp JV; Adam HK; Wakeling AE; Slater R
Biochem Pharmacol; 1983 Jul; 32(13):2045-52. PubMed ID: 6870933
[TBL] [Abstract][Full Text] [Related]
13. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
14. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.
Poon GK; Walter B; Lønning PE; Horton MN; McCague R
Drug Metab Dispos; 1995 Mar; 23(3):377-82. PubMed ID: 7628304
[TBL] [Abstract][Full Text] [Related]
15. Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28 days.
Chollet J; Mermelstein F; Rocamboli SC; Friend DR
Int J Pharm; 2019 Oct; 570():118691. PubMed ID: 31518632
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer.
Wilkinson P; Ribeiro G; Adam H; Patterson J
Cancer Chemother Pharmacol; 1980; 5(2):109-11. PubMed ID: 7471314
[TBL] [Abstract][Full Text] [Related]
17. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
18. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.
Poon GK; Chui YC; McCague R; Lłnning PE; Feng R; Rowlands MG; Jarman M
Drug Metab Dispos; 1993; 21(6):1119-24. PubMed ID: 7905393
[TBL] [Abstract][Full Text] [Related]
19. Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).
Murphy C; Fotsis T; Pantzar P; Adlercreutz H; Martin F
J Steroid Biochem; 1987 May; 26(5):547-55. PubMed ID: 3586671
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women.
Furlanut M; Franceschi L; Pasqual E; Bacchetti S; Poz D; Giorda G; Cagol P
Ther Drug Monit; 2007 Jun; 29(3):349-52. PubMed ID: 17529893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
